INTRODUCTION
Barrett's oesophagus is a pre-malignant condition of the distal oesophagus characterised by replacement of normal squamous epithelium with columnar epithelium. 1 Several recent studies have indicated that patients with Barrett's oesophagus have higher mortality than the general population, but that death due to oesophageal malignancy is not the primary underlying cause. [2] [3] [4] [5] This is consistent with the finding that the annual malignant transformation rate in Barrett's oesophagus is approximately 0.2%. [6] [7] [8] Evidence from different settings has indicated that cardiovascular diseases are the predominant underlying cause of death among patients with Barrett's oesophagus, probably partially exacerbated by shared risk factors such as obesity, smoking and alcohol consumption. 2, 3, [9] [10] [11] Given these findings, prophylactic screening for and treatment of cardiovascular diseases might be effective in patients with Barrett's oesophagus, and healthcare expenditures better utilised on prevention of cardiovascular diseases than on regular follow-up endoscopies to detect the rare event of oesophageal cancer. However, only sparse and conflicting population-based evidence exists on mortality in patients with Barrett's oesophagus. 2, [12] [13] [14] Furthermore, studies of causes of death, including cardiovascular death, are generally susceptible to misclassification. Thus, there is a need for assessment of the association between Barrett's oesophagus and cardiovascular events. 15, 16 In this context, we utilised a nationwide population-based cohort of histologically verified Barrett's oesophagus patients 6 first to examine overall and cause-specific mortality among patients with this condition and second to estimate their risk of cardiovascular events.
MATERIALS AND METHODS
We conducted this matched cohort study in the setting of the entire Danish population. During the study period (January 1, 1997 -December 31, 2011), the cumulative population numbered 6 849 900 people. Individual-level data were linked using the unique 10-digit personal identifier assigned at birth or upon immigration to all Danish residents by the Danish Civil Registration System. 17 Barrett's oesophagus cohort We used the Danish Pathology Registry to identify a cohort consisting of all Danish patients with histologically verified Barrett's oesophagus during the 1997-2011 period. 6, 18 Since January 1, 1997, this Registry has recorded data on all pathology examinations conducted in Denmark, including date of examination, unique ID number of the specimen, the pathology department code, and diagnosis based on the Danish Systemized Nomenclature of Medicine (SNOMED) codes. Patients joined the cohort on the date of their first diagnosis of Barrett's oesophagus (index date). (See Table S1 for diagnosis codes.) We excluded patients with a previous diagnosis of myocardial infarction, stroke, venous thromboembolism or heart failure, as these diseases comprised secondary study endpoints. Patients with Barrett's oesophagus were categorised in a time-varying manner according to severity of histology, i.e., low-grade dysplasia, high-grade dysplasia, and oesophageal cancer. We lacked information on the endoscopic appearance of the oesophagus or the length of Barrett's lesions.
Population comparison cohort
We used the Danish Civil Registration System 19 to match each patient with Barrett's oesophagus with 10 persons from the general population who were alive and without a Barrett's oesophagus diagnosis on the corresponding patient's diagnosis date (index date). Matching criteria were age (5-year intervals), sex and the individual conditions included in the Charlson Comorbidity Index (CCI). We applied the same exclusion criteria to the comparison cohort as for the Barrett's cohort. In the event that an individual from the comparison cohort developed Barrett's oesophagus during the study period, follow-up time was terminated and the individual joined the Barrett's cohort.
Study endpoints
Our primary endpoint was mortality, with information on date of death obtained from the Civil Registration System. 19 We ascertained causes of death from the Dan- Table S1 for codes.) We also subcategorised causes of cancer deaths by specific cancer site. Secondary endpoints were cardiovascular events, defined as a first-time diagnosis code of myocardial infarction, stroke, venous thromboembolism or heart failure. (See Table S1 
Comorbidity
We defined comorbidities according to the diagnoses included in the CCI, as recorded in the Danish National Patient Registry. 21 The CCI assigns weights between one and six to a range of conditions. (See Table S2 ). The conditions included in the CCI were not only considered individually for matching and analysis, but also as the components of a summed aggregate score that we classified as follows: score of 0 (no comorbidity), score of 1 (low comorbidity), and score 2 or more (high comorbidity). In addition to the conditions in the CCI, we included information on prior diagnoses of atrial fibrillation/flutter, obesity, hypertension and alcoholism. (See Table S1 for codes.)
Statistical analyses
Barrett's patients and members of the population comparison cohort were followed from index date until endpoint date, emigration or end of the study, whichever came first. We calculated mortality rates and incidence rates of cardiovascular diseases as the number of events divided by follow-up time. We used stratified Cox proportional hazard models to compute hazard ratios of mortality and cardiovascular events, comparing patients in the Barrett's cohort to individuals in the general population cohort. We computed hazard ratios for the first year of follow-up and for the second and subsequent years of follow-up separately to examine short-term vs. long-term mortality/risks. We also conducted an analysis excluding patients diagnosed with oesophageal cancer up to 30 days after the index date. We controlled for differences in age, sex and comorbidity through matching and additionally adjusted for atrial fibrillation, hypertension, obesity and alcoholism. In further analyses we did not adjust for atrial fibrillation and hypertension, since these factors may be intermediate factors along the causal pathway for the association of interest. In a time-varying analysis, we estimated mortality and risk of cardiovascular diseases by the histological severity of Barrett's oesophagus according to the following categories: no dysplasia, low-grade dysplasia, high-grade dysplasia and cancer. Patients contributed risk-time according to the histological severity of their Barrett's lesions at the beginning of follow-up and changed to a new category only in the event of increasing histological severity. To conduct this analysis, we dissolved the matching and adjusted for the matching factors.
In a subsequent analysis conducted to reduce bias due to uncontrolled confounding by lifestyle factors, we examined the relation between Barrett's oesophagus and mortality and cardiovascular events among subgroups of patients with diagnoses of chronic obstructive pulmonary disease (surrogate for smoking) or alcoholism.
RESULTS
We identified 13 427 patients with Barrett's oesophagus and 123 526 persons from the general population, matched by age, gender, year of index date and individual conditions in the CCI. Because we were unable to match all patients with Barrett's oesophagus to 10 persons from the general population, small differences occurred between the characteristics of the Barrett's oesophagus cohort and the general population comparison cohort (Table 1 ). Among patients with Barrett's oesophagus and members of the general population cohort, median age on the diagnosis/index date was 61 and 60 years, respectively, and average follow-up was 4 and 5 years, respectively. The vast majority (>80%) of patients with Barrett's oesophagus did not have dysplasia at diagnosis or during the course of follow-up.
Mortality
Patients with Barrett's oesophagus generally had higher rate of mortality than subjects in the matched general population cohort ( Figure 1 and Table 2 ). The overall mortality rate was 46.7 per 1000 person-years among patients with Barrett's oesophagus and 27.2 per 1000 person-years among subjects from the general population cohort, corresponding to an adjusted hazard ratio of 1.71 (95% CI: 1.64-1.78). The hazard ratio was nearly 3.2-fold increased in the first year of follow-up, but only 1.4-fold increased in the second and subsequent years of followup. For patients with Barrett's oesophagus, the highest mortality rates were associated with non-oesophageal cancer and diseases of the circulatory system. These two causes of deaths also were associated with the highest mortality rates in the general population cohort, although to a lesser degree ( Table 2 ). The mortality rate for oesophageal cancer was the third highest among all causes of death for patients with Barrett's oesophagus (disregarding the category of 'all other causes'), while among subjects in the general population cohort, oesophageal cancer had the lowest rate of all major causes of deaths. In a subanalysis, Barrett's oesophagus patients with known oesophageal cancer were excluded as of the Barrett's oesophagus diagnosis date (Table S3) . In this subanalysis, the mortality rate for oesophageal cancer decreased from 5.4 to 2.1 per 1000 person-years among Barrett's patients, and oesophageal cancer was associated with the lowest mortality rate of the major causes of death in this group.
Generally, the hazard ratios comparing cause-specific mortality among patients with Barrett's oesophagus and members of the general population cohort were increased. This was most pronounced for oesophageal cancer even when we excluded patients with known oesophageal cancer at diagnosis and diseases of the digestive system (Table 2 and Table S3 ). When we calculated hazard ratios without adjusting for atrial fibrillation and hypertension, the results did not change (not shown). Among non-oesophageal cancers, malignancies of the stomach, colorectum, lungs and thorax, and lymphoid, haematopoietic and other sites had the highest rates (Table 3) . When Barrett's oesophagus was evaluated by histological severity, the overall mortality rate increased with increasing histological severity. This pattern also was observed for mortality caused by neoplasia, particularly oesophageal cancer (Table 4) . For oesophageal cancer, the mortality rate was very low in the absence of dysplasia and for patients with low-grade dysplasia. It was only among Barrett's patients with oesophageal cancer that the mortality rate associated with this cancer exceeded the mortality rate associated with diseases of the circulatory system. We had too few observations to support an analysis of specific malignant causes of death according to severity of Barrett's oesophagus. When we evaluated deaths caused by diseases of the circulatory, respiratory and digestive system, the mortality rates did not change substantially by severity of Barrett's oesophagus and the mortality rate ratios were only modestly increased. Table 5 displays the incidence rates and hazard ratios showing the association between Barrett's oesophagus and different secondary endpoints. In general, patients with Barrett's oesophagus were at modestly increased risk of cardiovascular diseases compared to individuals in the general population cohort. Hazard ratios for secondary endpoints were very similar when the first year was compared to the second and subsequent years of follow-up, with the exception of risk of venous thromboembolism. Compared with the risks in the general population cohort, the risk of venous thromboembolism was 3.1-fold increased in the first year of follow-up and 1.4-fold increased in the second and subsequent years among Barrett's oesophagus patients. We found no substantial changes in risk of cardiovascular disease by histological severity of Barrett's oesophagus, although the risks appeared to increase slightly with increasing severity (Table S4) .
Cardiovascular diseases
Smoking and alcoholism Tables S5 shows hazard ratios of mortality and cardiovascular events within subgroups of Barrett's oesophagus patients with chronic obstructive pulmonary disease (surrogate for smoking) and alcoholism, compared to the general population cohort. The hazard ratios were attenuated towards the null for mortality and a few cardiovascular events. This might indicate some residual confounding by smoking and alcohol intake in the overall analysis.
DISCUSSION
In this nationwide population-based cohort study of patients with histologically verified Barrett's oesophagus, we found that overall mortality was 3.2-fold increased in the first year after diagnosis and 1.4-fold increased in the second and subsequent years, compared with an age-, sex-and comorbidity-matched general population cohort. Cause-specific mortality rates in the Barrett's oesophagus cohort were highest for non-oesophageal cancers and for cardiovascular diseases, followed by oesophageal cancer. When patients with known Numbers in parentheses are 95% confidence intervals.
* Matching criteria were age (5-year intervals), gender, year of index date, and comorbidity as defined by the Charlson Comorbidity Index.
oesophageal cancer on the date of their Barrett's oesophagus diagnosis were excluded from the analysis, the mortality attributable to oesophageal cancer was the lowest of the major causes of death among both the Barrett's oesophagus and general population cohorts. For nonoesophageal cancers, several malignancies contributed to the high cancer mortality rate among Barrett's oesophagus patients. The histological severity of Barrett's oesophagus impacted mortality caused by neoplasia overall, but affected mortality from other causes only slightly. Numbers in parentheses are 95% confidence intervals.
* Matching criteria were age (5-year intervals), gender, year of index, and comorbidity as defined by the Charlson Comorbidity Index.
We observed a modestly increased risk of cardiovascular events among Barrett's oesophagus patients, which was not substantially impacted by the histological severity of Barrett's oesophagus. The incidence rate of oesophageal adenocarcinoma within our cohort of patients with Barrett's oesophagus has previously been shown to be 1.2 (95% CI: 0.9-1.5) per 1000 person-years. 6 Our findings of increased overall mortality compared to the general population are supported by a recent population-based study utilising data from UK's Clinical Practice Research Datalink. 2 That study excluded deaths in the first year of follow-up and relied on Barrett's diagnoses from general practitioners rather than histologically verified diagnoses. Using individuals without Barrett's oesophagus as the comparison group, the study reported a mortality ratio of 1.21 (95% CI: 1.14-1.30), after adjusting for sex, age at diagnosis, smoking, alcohol consumption and body mass index. The study was an extension of a previous report by the same group and used the same data sources. 12 Its findings accord with at least five nonpopulation-based studies. 5, 9, 10, 22, 23 In contrast with the present study, the UK study 2 did not report an increased risk of cardiovascular death among patients with Barrett's oesophagus. However, it did find that diseases of the circulatory system, followed by non-oesophageal neoplasms, were the major underlying causes of death among patients with Barrett's oesophagus. Our study did not include data on treatment of Barrett's oesophagus. However, endoscopic ablative therapy was uncommon in our cohort during the study period. Our findings on causes of death are consistent with those of a recently published study including 4982 patients treated with radiofrequency ablation of Barrrett's oesophagus in the US. 11 In that study, the most common causes of death were non-oesophageal cancers and cardiovascular diseases. For unclear reasons, two previous population-based studies 13, 14 found no increase in overall mortality for patients with Barrett's oesophagus compared to the general population. An analysis 13 based on the Netherlands Cohort Study found an observed-to-expected ratio of overall mortality of 1.1 (95% CI: 0.9-1.2) after accounting for differences in age and sex, and a study 14 conducted in Northern Ireland reported an age-standardised mortality ratio of 0.96 (95% CI: 0.84-1.07). The current study extends existing evidence on mortality through its precise estimates and long-term follow-up of a large, nationwide cohort of patients with histologically verified Barrett's oesophagus. Our study also accounted for coexisting diseases and provided estimates according to histological severity. In addition, the study is the first to examine the specific association between Barrett's oesophagus and cardiovascular diseases. Such evidence is needed to foster an understanding of the possible increased risk of cardiovascular death among patients with Barrett's oesophagus and also to evaluate whether patients with Barrett's oesophagus should be offered cardiovascular screening or prophylactic treatment. Most, but not all, studies seem to agree that cardiovascular diseases are among the most frequent causes of death among patients with Barrett's oesophagus. 2, 3, 9, 10 We also found high mortality related to non-oesophageal cancers. Our findings, together with those of earlier studies, suggests that prophylactic measures against cardiovascular diseases and appropriate screening for non-oesophageal cancers potentially could be even more important for improving the prognosis of patients with Barrett's oesophagus, than prophylactic measures against oesophageal cancer, including surveillance endoscopy. This is especially true when one considers the questionable effectiveness of surveillance endoscopy in preventing death from oesophageal adenocarcinoma. 24 A previous population-based study reported a decreased risk of stroke death among patients with Barrett's oesophagus. It speculated that individuals with low vascular tone, and hence low blood pressure and stroke risk, also have disturbed oesophageal motor function, leading to gastrooesophageal reflux and development of Barrett's oesophagus.
14 However, our study did not confirm a decreased risk of stroke. It is also important to note that patients with Barrett's oesophagus have been reported to have a high prevalence of hypertension. 25 An inverse association between Barrett's oesophagus and stroke death based on a mechanism of decreased vascular tone/hypotension 13 therefore seems unlikely. Study strengths include its population-based cohort design and a setting that provides equal and free access to healthcare, essentially eliminating referral bias. Complete follow-up of all patients prevented selection bias due to drop-out. In addition, we included only Table 5 | Incidence rates and hazard ratios (HRs) of cardiovascular diseases in patients with Barrett's oesophagus and a matched general population cohort*, Denmark, 1997 Denmark, -2011 histologically verified diagnoses of Barrett's oesophagus and therefore limited biases stemming from exposure misclassification. Finally, we were able to include a population comparison cohort matched to the Barrett's cohort on age, gender, and all conditions included in the Charlson Comorbidity Index.
Our study also had several limitations. Among these, residual confounding from smoking, obesity and alcohol consumption is a serious concern, as indicated by the analyses within subgroups of individuals with chronic obstructive pulmonary disease or alcoholism. Our findings also may have been influenced by unknown confounding and by misclassification. Although it is generally accepted that a diagnosis of Barrett's oesophagus should rely on the correlation between endoscopic and pathological findings, 26 we used only pathological findings. It is therefore possible that cases of cardia intestinal metaplasia or ultrashort (< 1 cm) Barrett's oesophagus were included, although international guidelines advise against taking routine biopsies from the distal oesophagus in the absence of endoscopic signs of Barrett's oesophagus. 27 Although misclassification of our primary outcome (death) seems unlikely, it is wellknown that causes of death may be misclassified. 15, 16 We also cannot rule out misclassification of the secondary endpoints, cardiovascular events. Finally, since guidelines recommend regular follow-up of patients with Barrett's oesophagus, our findings may be influenced by surveillance bias.
In conclusion, we found that patients with Barrett's oesophagus were at 71% increased risk of overall mortality, and non-oesophageal cancers and cardiovascular diseases were the main underlying causes of death. In addition, the rate of cardiovascular diseases was increased. Prophylactic measures against cardiovascular diseases and appropriate screening for non-oesophageal cancers potentially could be even more important for improving prognosis in patients with Barrett's oesophagus than preventive measures against oesophageal cancer, including surveillance endoscopy.
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